Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

PHASE3CompletedINTERVENTIONAL
Enrollment

961

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Papulopustular Rosacea
Interventions
DRUG

Azelaic acid foam, 15% (BAY39-6251)

Azelaic acid twice daily topical application

DRUG

Vehicle foam

twice daily topical application

Trial Locations (49)

10029

New York

11790

Stony Brook

27103

Winston-Salem

27262

High Point

27517

Chapel Hill

27612

Raleigh

28602

Hickory

29621

Anderson

32086

Saint Augustine

32174

Ormond Beach

32258

Jacksonville

33027

Miramar

33144

Miami

33175

Miami

33437

Boynton Beach

35209

Birmingham

35233

Birmingham

35243

Birmingham

37922

Knoxville

40202

Louisville

40475

Richmond

46168

Plainfield

48088

Warren

48322

West Bloomfield

55432

Fridley

60089

Buffalo Grove

60625

Chicago

63141

St Louis

68144

Omaha

70124

New Orleans

75093

Plano

77598

Webster

78759

Austin

80915

Colorado Springs

84117

Salt Lake City

89128

Las Vegas

89144

Las Vegas

90045

Los Angeles

90404

Santa Monica

92103

San Diego

92705

Santa Ana

94538

Fremont

95816

Sacramento

98101

Seattle

99204

Spokane

94143-0660

San Francisco

33472-2952

Boynton Beach

08520

East Windsor

02919

Johnston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
lead

LEO Pharma

INDUSTRY

collaborator

Bayer

INDUSTRY